169 related articles for article (PubMed ID: 37538173)
1. The pharmacokinetic profile of brensocatib and its effect on pharmacodynamic biomarkers including NE, PR3, and CatG in various rodent species.
Basso J; Chen KJ; Zhou Y; Mark L; LaSala D; Dorfman A; Atalla M; Chun D; Viramontes V; Chang C; Leifer F; McDonald PP; Cipolla DC
Front Pharmacol; 2023; 14():1208780. PubMed ID: 37538173
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Cipolla D; Zhang J; Korkmaz B; Chalmers JD; Basso J; Lasala D; Fernandez C; Teper A; Mange KC; Perkins WR; Sullivan EJ
Respir Res; 2023 May; 24(1):133. PubMed ID: 37198686
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.
Chalmers JD; Usansky H; Rubino CM; Teper A; Fernandez C; Zou J; Mange KC
Clin Pharmacokinet; 2022 Oct; 61(10):1457-1469. PubMed ID: 35976570
[TBL] [Abstract][Full Text] [Related]
4. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1, mitigates interferon-α-accelerated lupus nephritis in mice.
Chen KJ; Zhang J; LaSala D; Basso J; Chun D; Zhou Y; McDonald PP; Perkins WR; Cipolla DC
Front Immunol; 2023; 14():1185727. PubMed ID: 37441081
[TBL] [Abstract][Full Text] [Related]
5. BI 1291583: a novel selective inhibitor of cathepsin C with superior in vivo profile for the treatment of bronchiectasis.
Kreideweiss S; Schänzle G; Schnapp G; Vintonyak V; Grundl MA
Inflamm Res; 2023 Aug; 72(8):1709-1717. PubMed ID: 37542002
[TBL] [Abstract][Full Text] [Related]
6. Brensocatib (an oral, reversible inhibitor of dipeptidyl peptidase-1) attenuates disease progression in two animal models of rheumatoid arthritis.
McDonald PP; Leifer FG; Basso J; Lasala D; Li D; Chen KJ; Zhang J; Perkins WR; Cipolla DC
Front Immunol; 2023; 14():1231047. PubMed ID: 37638021
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD; Haworth CS; Metersky ML; Loebinger MR; Blasi F; Sibila O; O'Donnell AE; Sullivan EJ; Mange KC; Fernandez C; Zou J; Daley CL;
N Engl J Med; 2020 Nov; 383(22):2127-2137. PubMed ID: 32897034
[TBL] [Abstract][Full Text] [Related]
8. Periodontal Effects of the Reversible Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Bronchiectasis.
Gunsolley JC; Chalmers JD; Sibila O; Fernandez C; Scannapieco FA
JDR Clin Trans Res; 2023 Sep; ():23800844231196884. PubMed ID: 37746735
[TBL] [Abstract][Full Text] [Related]
9. Cathepsin C inhibition as a potential treatment strategy in cancer.
Korkmaz B; Lamort AS; Domain R; Beauvillain C; Gieldon A; Yildirim AÖ; Stathopoulos GT; Rhimi M; Jenne DE; Kettritz R
Biochem Pharmacol; 2021 Dec; 194():114803. PubMed ID: 34678221
[TBL] [Abstract][Full Text] [Related]
10. N-Arylacyl O-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin G and proteinase 3.
Craciun I; Fenner AM; Kerns RJ
Glycobiology; 2016 Jul; 26(7):701-709. PubMed ID: 26850997
[TBL] [Abstract][Full Text] [Related]
11. Targeting Cathepsin C in PR3-ANCA Vasculitis.
Jerke U; Eulenberg-Gustavus C; Rousselle A; Nicklin P; Kreideweiss S; Grundl MA; Eickholz P; Nickles K; Schreiber A; Korkmaz B; Kettritz R
J Am Soc Nephrol; 2022 May; 33(5):936-947. PubMed ID: 35292437
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity.
Gardiner P; Wikell C; Clifton S; Shearer J; Benjamin A; Peters SA
Br J Pharmacol; 2016 Aug; 173(15):2390-401. PubMed ID: 27186823
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults.
Usansky H; Yoon E; Teper A; Zou J; Fernandez C
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):832-842. PubMed ID: 35411669
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl Peptidase 1 Inhibitor AZD7986 Induces a Sustained, Exposure-Dependent Reduction in Neutrophil Elastase Activity in Healthy Subjects.
Palmér R; Mäenpää J; Jauhiainen A; Larsson B; Mo J; Russell M; Root J; Prothon S; Chialda L; Forte P; Egelrud T; Stenvall K; Gardiner P
Clin Pharmacol Ther; 2018 Dec; 104(6):1155-1164. PubMed ID: 29484635
[TBL] [Abstract][Full Text] [Related]
15. Association of admission neutrophil serine proteinases levels with the outcomes of acute ischemic stroke: a prospective cohort study.
Li L; Han Z; Wang R; Fan J; Zheng Y; Huang Y; Yang Z; Yan F; Liu P; Zhao H; Ma Q; Luo Y
J Neuroinflammation; 2023 Mar; 20(1):70. PubMed ID: 36906528
[TBL] [Abstract][Full Text] [Related]
16. Neutrophil proteases are protective against SARS-CoV-2 by degrading the spike protein and dampening virus-mediated inflammation.
Leborgne NG; Devisme C; Kozarac N; Berenguer Veiga I; Ebert N; Godel A; Grau-Roma L; Scherer M; Plattet P; Thiel V; Zimmer G; Taddeo A; Benarafa C
JCI Insight; 2024 Apr; 9(7):. PubMed ID: 38470488
[TBL] [Abstract][Full Text] [Related]
17. Neutrophils and neutrophil serine proteases are increased in the spleens of estrogen-treated C57BL/6 mice and several strains of spontaneous lupus-prone mice.
Dai R; Cowan C; Heid B; Khan D; Liang Z; Pham CT; Ahmed SA
PLoS One; 2017; 12(2):e0172105. PubMed ID: 28192517
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil Elastase and Proteinase 3 Cleavage Sites Are Adjacent to the Polybasic Sequence within the Proteolytic Sensitive Activation Loop of the SARS-CoV-2 Spike Protein.
Mustafa Z; Zhanapiya A; Kalbacher H; Burster T
ACS Omega; 2021 Mar; 6(10):7181-7185. PubMed ID: 33748632
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease.
Chalmers JD; Kettritz R; Korkmaz B
Front Immunol; 2023; 14():1239151. PubMed ID: 38162644
[TBL] [Abstract][Full Text] [Related]
20. Premedication with a cathepsin C inhibitor alleviates early primary graft dysfunction in mouse recipients after lung transplantation.
Rehm SRT; Smirnova NF; Morrone C; Götzfried J; Feuchtinger A; Pedersen J; Korkmaz B; Yildirim AÖ; Jenne DE
Sci Rep; 2019 Jul; 9(1):9925. PubMed ID: 31289357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
